ATRECA Canadian Trademark Information

On Thursday, January 24, 2019, a canadian trademark registration was filed for ATRECA by ATRECA, INC. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1942441. The current status of this trademark filing is Registration published. The ATRECA trademark is filed in the description of Diagnostic preparations and diagnostic kits comprised of buffers and reagents for clinical, medical laboratory, or research use; biological tissue cultures for research and scientific diagnosis use; antibodies reagents for research and scientific diagnosis use; combinations of biological tissue cultures for research and scientific diagnosis use; combinations of antibody reagents for research and scientific diagnosis use; kits containing buffers and chemical reagents for use in molecular biology research; , Diagnostic preparations and diagnostic kits comprised of buffers and reagents for clinical, medical laboratory, or research use; biological tissue cultures for research and scientific diagnosis use; antibodies reagents for research and scientific diagnosis use; combinations of biological tissue cultures for research and scientific diagnosis use; combinations of antibody reagents for research and scientific diagnosis use; kits containing buffers and chemical reagents for use in molecular biology research; , Biological assays consisting primarily of monoclonal antibodies, pre-made buffer concentrates, and chemical reagents for clinical use and scientific research in the fields of biological and diagnostic testing for industrial, scientific and research use; biological tissue cultures for research and scientific diagnosis use; antibodies reagents for research and scientific diagnosis use; combinations of antibodies for clinical use and scientific research in the fields of biological and diagnostic testing for industrial, scientific and research use , Diagnostic preparations and diagnostic kits comprised of buffers and reagents for medical use, for predicting the response of patients to therapeutics; biologics for medical use, namely, biological preparation for the treatment of infectious disease; biologics for medical use, namely, biological preparation for the treatment of cancer; biologics for medical use, namely, biological preparation for the treatment of autoimmune disease; biologics for medical use, namely, biological preparation for the treatment of cardiovascular disease; biologics for medical use, namely, biological preparation for the treatment of animal diseases; biologics, namely, biological tissue cultures for medical diagnosis; biologics, namely, antibodies for medical diagnosis; biologics, namely, vaccines for medical diagnosis, research and scientific diagnosis; combinations of biologics for medical use, namely, biological preparation for the treatment of infectious disease; combinations of biologics for medical use, namely, biological preparation for the treatment of cancer; combinations of biologics for medical use, namely, biological preparation for the treatment of autoimmune disease; combinations of biologics for medical use, namely, biological preparation for the treatment of cardiovascular disease; combinations of biologics for medical use, namely, biological preparation for the treatment of animal diseases; combinations of biologics, namely, biological tissue cultures, antibodies, and vaccines, for medical diagnosis; , Diagnostic preparations and diagnostic kits comprised of buffers and reagents for medical use, for predicting the response of patients to therapeutics; biologics for medical use, namely, biological preparation for the treatment of infectious disease; biologics for medical use, namely, biological preparation for the treatment of cancer; biologics for medical use, namely, biological preparation for the treatment of autoimmune disease; biologics for medical use, namely, biological preparation for the treatment of cardiovascular disease; biologics for medical use, namely, biological preparation for the treatment of animal diseases; biologics, namely, biological tissue cultures for medical diagnosis; biologics, namely, antibodies for medical diagnosis; biologics, namely, vaccines for medical diagnosis, research and scientific diagnosis; combinations of biologics for medical use, namely, biological preparation for the treatment of infectious disease; combinations of biologics for medical use, namely, biological preparation for the treatment of cancer; combinations of biologics for medical use, namely, biological preparation for the treatment of autoimmune disease; combinations of biologics for medical use, namely, biological preparation for the treatment of cardiovascular disease; combinations of biologics for medical use, namely, biological preparation for the treatment of animal diseases; combinations of biologics, namely, biological tissue cultures, antibodies, and vaccines, for medical diagnosis; , Biological assays for medical use, namely, biological preparations for the treatment or prophylaxis of cancer; pharmaceutical preparations, namely biologics for the treatment or prophylaxis of infectious diseases; pharmaceutical preparations, namely, biologics and antibodies for the treatment of oncological disorders and conditions; biologics for medical use, namely, biological preparation for the treatment of autoimmune disease; biologics for medical use, namely, biological preparation for the treatment of cardiovascular disease; biologic pharmaceutical preparations, namely, antibodies for use with diagnostic agents for the diagnosis of oncological diseases, disorders and conditions in humans; combinations of biologics for medical use, namely, biological preparation for the treatment of autoimmune disease; combinations of biologics for medical use, namely, biological preparation for the treatment of cardiovascular disease .